WO2023187715 - COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/187715
Publication Date
05.10.2023
International Application No.
PCT/IB2023/053202
International Filing Date
30.03.2023
Title **
[English]
COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF
[French]
INHIBITEURS DU FACTEUR B DU COMPLÉMENT ET LEURS UTILISATIONS
Applicants **
NOVARTIS AG
Inventors
CZABANIUK, Lara C.
HEDIGER, Michael Christoph
HURTH, Konstanze
SENDZIK, Martin
LABBE-GIGUERE, Nancy
VULPETTI, Anna
Priority Data
63/326,532
01.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6435 | |
| EPO | Filing, Examination, Granting | 140071 | |
| Japan | Filing, Examination, Granting | 5205 | |
| South Korea | Filing, Examination, Granting | 10584 | |
| USA | Filing, Examination, Granting | 86640 |
Total:
248,935
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B.[French]
L'invention concerne des composés de formule (I) et des compositions pharmaceutiques associées utiles pour le traitement de maladies ou de troubles médiés par le facteur B du complément.